AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02742649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol
Description: Continuous elution from the ocular insert. This is an active control arm.
Study NCT02742649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Segment
Description: One segment of placebo (no drug product)
Study NCT02742649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Description: 0.5% timolol drops twice daily.
Study NCT01959867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SurgiMend® PRS
Description: Subjects enrolled in to this cohort will receive SurgiMend® PRS (ADM) product during the first stage of the reconstruction (expander insertion).
Study NCT01959867 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: Subjects enrolled in to this cohort will not receive an acellular dermal matrix (ADM) product during the first stage of the reconstruction (expander insertion).
Study NCT01465737 — intervention group
Intervention type: OTHER
Intervention: Histologic types
Description: evaluate survival among different histologic types
Study NCT01666236 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Triple Therapy
Description: The treatment (single group) will be treated with reduced-fluence Photodynamic Therapy (Visudyne -Verteporfin infused over 10 minutes at a dose of 6mg/m2 and following by activating light \[wavelength of 689 nm\] applied 15 minutes after the start of infusion with a light dose of either 25 J/cm2 for 83 seconds), followed by an Intra-vitreous triamcinolone (4mg/0.1ml) on the same day.~After 10 days, patients will be subjected to an injection of Intra-vitreous ranibizumab (0.5 mg/0.05 ml). After this first injection, Intra-vitreous ranibizumab will be repeated twice, on a monthly basis, for a total of three injections
Study NCT02666534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine-prilocaine 5% cream application
Description: The lesions were then cleansed with saline gauze, and a lidocaine-prilocaine 5% cream (EMLA®; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area for 30 min under occlusion
Study NCT02666534 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2940-nm Er:YAG AFL pretreatment
Description: After the anesthetic cream was removed, AFL was performed using a 2940-nm Er:YAG AFL (Joule; Sciton, Inc., Palo Alto, CA, USA) with a 500 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse
Study NCT02666534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methyl-aminolevulinate application
Description: Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.
Study NCT02666534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methyl-aminolevulinate application
Description: Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.
Study NCT02666534 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Illuminating using red light-emitting diode lamps
Description: Each treatment area was then separately illuminated using red light-emitting diode lamps (Aktilite CL128; Galderma S.A., Bruchsal, Germany) with peak emission at 632 nm and a total light dose of 37 J/cm2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later. During the illumination, patients were asked to evaluate pain intensity using an 11-point visual analog scale.
Study NCT02666534 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Illuminating using red light-emitting diode lamps
Description: Each treatment area was then separately illuminated using red light-emitting diode lamps (Aktilite CL128; Galderma S.A., Bruchsal, Germany) with peak emission at 632 nm and a total light dose of 37 J/cm2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later. During the illumination, patients were asked to evaluate pain intensity using an 11-point visual analog scale.
Study NCT04948567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: split-dose of Magnesium Sulfate solution
Description: purgative for bowel preparation
Study NCT04948567 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: split-dose of PEG
Description: purgative for bowel preparation
Study NCT00881478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition counseling + portion control tool
Description: Nutrition counseling with registered dietician in addition to teaching about how use of a portion control tool
Study NCT00881478 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition counseling
Description: Nutrition counseling with registered dietician
Study NCT03759288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab low dose
Description: Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
Study NCT03759288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab high dose
Description: Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
Study NCT03759288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humira®
Description: Administered subcutaneously on Day 1, Day 15, and Day 29 and every 2 weeks through Week 50.
Study NCT03759288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous placebo on Days 1, 29, 57 followed by subcutaneous placebo on Day 85 and every 4 weeks through Week 48
Study NCT02382601 — intervention group
Intervention type: RADIATION
Intervention: Ultrasound
Description: With 3-D and 4-D high-resolution color Doppler methods it is possible to map out the placental circulation, fetal circulation, fetal brain, and fetal cardiac function. Investigators will collect these data points prenatally.
Study NCT02382601 — intervention group
Intervention type: RADIATION
Intervention: MRI
Description: Similar to the Ultrasound data, investigators will collect MRI images of the fetal brain and the placenta. MRI will allow investigators to collect more detailed images of both the fetal brain and placenta, and investigators will be utilizing this technique both prenatally and postnatally.
Study NCT02382601 — intervention group
Intervention type: PROCEDURE
Intervention: Blood collection
Description: The maternal and cord blood will be collected for the processing of plasma and serum. There may be early biomarkers of IUGR in the maternal circulation that investigators can use to better determine the appropriate strategy for clinical management of care. Collection and subsequent analysis of molecular markers in the umbilical cord blood will be used to further confirm physiological dysfunction as detected by ultrasound and MRI techniques.
Study NCT02382601 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neurological Function Assessment
Description: Neurological development tests including a Bayley exam, Mullen exam, Developmental Profile-3, Child Behavior Checklist, and Pediatric Stroke Outcome Measure (PSOM) will be performed.
Study NCT00409240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MEDIC
Description: Multidisciplinary Education and Diabetes Intervention for Cardiac risk reduction (MEDIC; a pharmacist-led behavioral and pharmacologic intervention in groups.
Study NCT03261635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab Injection
Description: patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata
Study NCT03261635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab Injection
Description: patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata
Study NCT03261635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: patients self-administered one drop of indomethacin 0.5% eye drops three times a day for 12 months
Study NCT06204523 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: investigated biomarkers regarding the efficacy of first-line chemotherapy
Description: The present study was designed to generate solid evidence on the predictivity of the investigated biomarkers regarding the efficacy of first-line chemotherapy in patients with GC
Study NCT02818816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brimonidine tartrate 0.2%
Description: Alpha adrenergic receptor agonist
Study NCT02818816 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Carboxymethylcellulose Eye Drops
Description: Ocular lubricants
Study NCT02382601 — intervention group
Intervention type: PROCEDURE
Intervention: Placental Analysis
Description: Placentas will undergo pathological evaluation for placental function.
Study NCT02382601 — intervention group
Intervention type: PROCEDURE
Intervention: Measurement of body fat
Description: The baby's body fat will be measured in a special incubator called a PEAPOD or BODPOD when an infant.
Study NCT02382601 — intervention group
Intervention type: RADIATION
Intervention: Pediatric heart ultrasound
Description: Children will have ultrasounds of their hearts during follow-up visits.
Study NCT03151421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home air quality monitoring and feedback
Description: Two-hundred smokers (50 in each country) will be recruited and offered low-cost, simple to operate particle counting instruments to measure and log SHS levels in their home for a period of 30 days. During this time near real-time, personalised feedback will be provided to, and discussed with, the smoker along with target-setting and exploration of suitable methods of behaviour-change. Feedback will be given via text message to mobile phones, emails and personal voicecalls. A final visit will gather data on changes made while a proportion of participants (10-20%) in each country will take part in a further qualitative interview by phone to gather data on their experience of the intervention.
Study NCT02349113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogens (Climara)
Description: Treatment with estrogens: Estradiol dermal patch 0.1mg/d transdermally
Study NCT04798703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)
Description: 12 weekly intravesical instillations of ONCOFID-P-B™ (intensive treatment phase) followed by maintenance phase of the study, during which ONCOFID-P-B™ is furtherly administered once a month for 12 months in patients who achieved a complete response (CR) after the 12 weekly instillations.
Study NCT01427907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium acetate oral solution (COS)
Description: Each subject will undergo two separate treatment periods. Subjects will ingest either COS or sevelamer for 28 days (Treatment Period 1) and then switch to the other binder for 28 days (Treatment Period 2).
Study NCT01427907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer carbonate
Description: Each subject will undergo two separate treatment periods. Subjects will ingest either COS or sevelamer for 28 days (Treatment Period 1) and then switch to the other binder for 28 days (Treatment Period 2).
Study NCT02402179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tryptophan
Description: Tryptophan will be supplied at 13.2, 26.4, 39.7, or 52.9% of requirement; sourced from crystalline amino acid and white cornmeal maize.
Study NCT03783533 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Intervention: Behavioral Activation (BA) therapy is based on a functional analytic model of depression that highlights the need for increased positive reinforcement (rewards) and decreased anhedonia, or diminished motivation to seek rewards, to maintain normal mood. BA is significantly more effective than Cognitive Behavioral Therapy and comparable to antidepressant medication in reducing depressive symptoms among depressed adults (Dimidjian et al., 2006). McCauley (senior mentor) et al. (2016) adapted BA for adolescents to target anhedonia, effective problem solving and avoidant behaviors with peers, family, and school. McCauley's findings and others show BA is a promising intervention for adolescent MDD (Chu et al., 2009; Cuijpers et al.,, 2007; McCauley et al., 2015; Ritschel et al., 2011). BA focuses on targeting ideographically identified avoidant behaviors and rewarding experiences that affect mood.
Study NCT00591747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: 60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
Study NCT00591747 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility Training
Description: 60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
Study NCT02815631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiogoniometry (CGM)
Study NCT02815631 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Flow Reserve (FFR)
Study NCT03987581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Twelve in-person counseling sessions designed to assist participants with becoming abstinent from alcohol use (or reduce use).
Study NCT03987581 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Twelve in-person counseling sessions designed to assist participants with becoming abstinent from alcohol use (or reduce use).
Study NCT03987581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Contingency Management (mCM)
Description: Abstinence (measured by breath alcohol) will be intermittently reinforced. For each breath alcohol concentration reading that tests negative, a participant will earn a virtual scratch-off lottery ticket that contains 100 different values.
Study NCT03987581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Long-term incentive
Description: This incentive is $300 for self-reported and bioverified 30-day abstinence from heavy drinking at the follow-up scheduled for 6-months after the initial quit date
Study NCT01994733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium carbonate ( Intensive phosphate control)
Description: Individuals randomized to this arm will be exposed to a treatment strategy that targets a P of \< 1.50 mmol/L, reflecting the recommendations of current guidelines. Titration of the calcium carbonate dose will be the core of this approach and this will be complemented by usual recommendations regarding dietary P restriction. Dietitians will be available to provide counseling with regards to any aspect of the end-stage renal disease diet, as per usual dialysis unit practice
Study NCT01994733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate (Liberalized phosphate control)
Description: Individuals in this arm will be exposed to a treatment strategy that allows P to rise above 2.00 mmol/L. This will be accomplished through structured reduction of P binders already in use (as per the algorithm detailed below). Rescue P binding will be instituted if P rises above 2.50 mmol/L. Dietitians will be available to provide counseling regarding any aspect of the end-stage renal disease diet, as per usual dialysis unit practice, but will not provide counseling on dietary P restriction unless the P rises above 2.50 mmol/L.
Study NCT03417973 — intervention group
Intervention type: DEVICE
Intervention: dorsal root ganglion neuromodulation
Description: stimulation for neuromodulation of the dorsal root ganglion
Study NCT00293462 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sargramostim
Study NCT01149278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: maintain mean arterial pressure between 80-85 mm Hg
Description: protocolized hemodynamic care aiming to maintain mean arterial pressure between 80-85 mm Hg
Study NCT01149278 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: maintain mean arterial pressure between 65-70 mm Hg
Description: protocolized hemodynamic care aiming to maintain mean arterial pressure between 65-70 mm Hg
Study NCT02559232 — intervention group
Intervention type: DRUG
Intervention: Direct Oral Anticoagulant (DOAC)
Description: Treatment pattern following the summary of product characteristics
Study NCT01912872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Subcutaneous injection dose according to the IgE level and body weight.
Study NCT01912872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Budesonide (400 μg, 200 μg or 100 μg) tablets taken orally according to maximum daily dose.
Study NCT00293462 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral salt and soda mouthwash
Description: Patients receive oral salt and soda mouthwash, holding it and swallowing it in intervals over 1 hour once daily.
Study NCT03393520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsules
Study NCT01912872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide (400 μg, 200 μg or 100 μg) tablets taken orally according to maximum daily dose.
Study NCT01912872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Formoterol 12ug tablets taken orally according to maximum daily dose.
Study NCT01912872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Formoterol 12ug tablets taken orally according to maximum daily dose.
Study NCT01912872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Budesonide (400 μg, 200 μg or 100 μg). Patients were instructed to take the inhaled budesonide doses every 12 hours following the specific administration instructions as per the manufactures' prescription information.
Study NCT01912872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide (400 μg, 200 μg or 100 μg). Patients were instructed to take the inhaled budesonide doses every 12 hours following the specific administration instructions as per the manufactures' prescription information.
Study NCT01912872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Formoterol 12ug. Patients were instructed to take the inhaled formoterol doses every 12 hours following the specific administration instructions as per the manufactures' prescription information.
Study NCT02205385 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted Muscle Reinnervation
Study NCT02205385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traction Neurectomy
Study NCT03042611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoceranib
Description: Oral tablet
Study NCT03973489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Description: On visits 2 and 3, subjects will undergo a baseline MRI scan approximately 1 hour after the start of each visit followed by drug administration (placebo or MA) and a second scan 1.5 hours after that.
Study NCT03393520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786
Description: oral capsules
Study NCT01628874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J-Tip
Description: Used once for both arms prior to lumbar puncture. The Experimental arm will receive 0.5 mL (5mg) of 1% Lidocaine. The Active Comparator arm will receive normal saline. This will occur after the cream has been placed for 30 minutes and wiped away and prior to the lumbar puncture.
Study NCT01628874 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: J-Tip
Description: Used once for both arms prior to lumbar puncture. The Experimental arm will receive 0.5 mL (5mg) of 1% Lidocaine. The Active Comparator arm will receive normal saline. This will occur after the cream has been placed for 30 minutes and wiped away and prior to the lumbar puncture.
Study NCT01628874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA
Description: In the Active Comparator arm, lidocaine 2.5% and prilocaine 2.5% cream placed over area where lumbar puncture will occur for at least 30 minutes. This same procedure will occur for the Experimental arm with a placebo cream instead. This will occur once prior to the J-Tip injection and lumbar puncture.
Study NCT03042611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablet